NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,889,195 | -24.6% | 410,468 | -0.3% | 0.01% | -20.0% |
| Q2 2023 | $10,463,864 | -17.3% | 411,639 | +17.5% | 0.01% | -23.1% |
| Q1 2023 | $12,660,273 | -39.6% | 350,215 | -33.8% | 0.01% | -40.9% |
| Q4 2022 | $20,945,708 | -13.6% | 528,932 | +1.7% | 0.02% | -18.5% |
| Q3 2022 | $24,231,000 | +6.3% | 519,992 | -0.0% | 0.03% | +12.5% |
| Q2 2022 | $22,791,000 | -39.6% | 519,997 | -0.3% | 0.02% | -25.0% |
| Q1 2022 | $37,717,000 | -9.8% | 521,478 | +1.1% | 0.03% | +45.5% |
| Q4 2021 | $41,815,000 | -31.4% | 515,783 | -1.6% | 0.02% | -35.3% |
| Q3 2021 | $60,993,000 | -29.6% | 524,092 | +0.2% | 0.03% | -26.1% |
| Q2 2021 | $86,611,000 | +2.0% | 523,178 | -14.0% | 0.05% | +7.0% |
| Q1 2021 | $84,901,000 | +14.4% | 608,612 | +41.9% | 0.04% | +19.4% |
| Q4 2020 | $74,229,000 | +24.6% | 428,825 | +0.3% | 0.04% | 0.0% |
| Q3 2020 | $59,564,000 | +12.1% | 427,595 | -3.8% | 0.04% | -5.3% |
| Q2 2020 | $53,130,000 | +63.8% | 444,716 | +37.1% | 0.04% | +35.7% |
| Q1 2020 | $32,429,000 | -11.3% | 324,353 | +4.2% | 0.03% | +3.7% |
| Q4 2019 | $36,574,000 | +42.6% | 311,173 | +4.3% | 0.03% | +22.7% |
| Q3 2019 | $25,646,000 | -27.9% | 298,309 | -45.6% | 0.02% | -29.0% |
| Q2 2019 | $35,549,000 | +4.1% | 548,345 | +0.3% | 0.03% | 0.0% |
| Q1 2019 | $34,165,000 | +47.5% | 546,539 | -8.3% | 0.03% | +29.2% |
| Q4 2018 | $23,167,000 | -25.2% | 595,759 | +9.7% | 0.02% | -14.3% |
| Q3 2018 | $30,956,000 | +13.6% | 543,067 | +59.1% | 0.03% | +3.7% |
| Q2 2018 | $27,259,000 | -13.5% | 341,381 | -6.2% | 0.03% | -6.9% |
| Q1 2018 | $31,527,000 | +70.4% | 363,775 | +35.7% | 0.03% | +70.6% |
| Q4 2017 | $18,501,000 | +343.2% | 267,976 | +483.5% | 0.02% | +325.0% |
| Q3 2017 | $4,174,000 | +351.7% | 45,929 | +270.2% | 0.00% | +300.0% |
| Q2 2017 | $924,000 | -87.3% | 12,408 | -84.1% | 0.00% | -85.7% |
| Q1 2017 | $7,297,000 | +261.8% | 77,876 | +180.5% | 0.01% | +250.0% |
| Q4 2016 | $2,017,000 | -19.0% | 27,761 | +16.3% | 0.00% | 0.0% |
| Q3 2016 | $2,491,000 | +11.7% | 23,874 | -21.1% | 0.00% | 0.0% |
| Q2 2016 | $2,231,000 | +355.3% | 30,249 | +247.1% | 0.00% | +100.0% |
| Q1 2016 | $490,000 | +18.1% | 8,714 | +42.0% | 0.00% | – |
| Q4 2015 | $415,000 | -27.6% | 6,135 | -50.3% | 0.00% | -100.0% |
| Q3 2015 | $573,000 | -45.4% | 12,356 | -36.7% | 0.00% | 0.0% |
| Q2 2015 | $1,049,000 | +277.3% | 19,529 | +171.5% | 0.00% | – |
| Q4 2014 | $278,000 | – | 7,192 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |